Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

Next Previous
Trial Profile

A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemrametostat (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Glioblastoma; Head and neck cancer; Male breast cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Ureteral neoplasms
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms METEOR-1
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 12 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 13 Sep 2022 Results reporting safety and efficacy data from part 2 dose expansion phase of this trial presented at the 47th European Society for Medical Oncology Congress
    • 23 Jun 2022 Planned End Date changed from 29 Apr 2025 to 31 Aug 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top